News BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Delayed Nasdaq Other stock markets 03:43:40 2024-04-26 pm EDT			5-day change	1st Jan Change
2.595 ^USD	-0.57%		-5.64%	-12.03%

Apr. 22	BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	MT
Apr. 22	BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024	Apr. 25	AQ
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting	Apr. 24	AQ
BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	Apr. 22	MT
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	Apr. 22	AQ
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential	Apr. 22	CI
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia	Apr. 10	AQ
Bioxcel Therapeutics, Inc. Announces Transquility In-Care Pivotal Phase 3 Trial Plan with Bxcl501 for Agitation Associated with Alzheimer's Dementia	Apr. 10	CI
BioXcel Therapeutics Prices $25 Million Registered Direct Offering of Shares, Warrants	Mar. 25	MT
BioXcel Therapeutics Announces $25 Million Registered Direct Offering	Mar. 25	AQ
BioXcel Therapeutics Gets European Patent for Method of Treating Agitation in Dementia	Mar. 15	MT
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine	Mar. 15	AQ
Canaccord Genuity Cuts Price Target on BioXcel Therapeutics to $7 From $20, Maintains Buy Rating	Mar. 14	MT
UBS Adjusts BioXcel Therapeutics Price Target to $3.50 From $4, Maintains Neutral Rating	Mar. 13	MT
Transcript : BioXcel Therapeutics, Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
BioXcel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 12	CI
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023	Mar. 12	AQ
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024	Mar. 01	AQ
North American Morning Briefing : Nvidia Ignites -2-	Feb. 22	DJ
UBS Downgrades BioXcel Therapeutics to Neutral From Buy, Cuts Price Target to $4 From $9	Feb. 21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioXcel Therapeutics, Inc.

Equities

BTAI

US09075P1057

Summary

Filters